Gentian Diagnostics reports strong Q3 2025 results with significant growth

Gentian Diagnostics ASA reported Q3 2025 sales of NOK 41.8 million, a 28% increase (31% organic) compared to Q3 2024, contributing to year-to-date 2025 sales of NOK 129.9 million, up 19% organically. EBITDA for Q3 2025 reached NOK 8.4 million, up from NOK 5.0 million in Q3 2024, with year-to-date EBITDA of NOK 24.1 million, an improvement over the NOK 16.5 million reported for the same period last year. The gross margin also saw an increase to 56% in Q3 2025 from 52% in Q3 2024, indicating improved operational efficiency.

The strong performance was notably driven by Cystatin C sales, which surged by 73% in Q3 2025 due to robust growth in the US market, with year-to-date sales to the US reaching NOK 21.7 million. This growth was partly attributed to new accounts acquired in 2025 and a warehouse shift for a major customer. Significant progress was also made on pipeline projects, with NT-proBNP moving closer to verification for a targeted commercial launch in Q4 2026, and a major IVD company development project advancing to its optimization phase.

The company's strategic pillars, including expanding market access and proving clinical relevance of products like GCAL and NT-proBNP, underpin its long-term growth. Gentian also aims to secure one new global commercial partner annually and achieve long-term EBITDA margins of 40%. The JIA COMPASS study, evaluating GCAL in children, has enrolled approximately 70 patients across several activated sites, further validating the diagnostic and prognostic use of its products.